Evidence map›Paper›PMID 25046437›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2014

Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis.

James H Tabibian, Christy E Trussoni, Steven P O'Hara, Patrick L Splinter, Julie K Heimbach, Nicholas F LaRusso

Open access · bronzeAbstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Update on Hepatobiliary Plasticity.Seminars in liver disease · 2023
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

James H Tabibian1] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Center for Cell Signaling in Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN, USA.ORCID 0000000191041702
Christy E Trussoni1] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Center for Cell Signaling in Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Steven P O'Hara1] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Center for Cell Signaling in Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Patrick L Splinter1] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Center for Cell Signaling in Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Julie K HeimbachDivision of Transplantation Surgery, Mayo Clinic, Rochester, MN, USA.
Nicholas F LaRusso1] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA [2] Center for Cell Signaling in Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
MULTIDISCRIPLINARY TRAINING IN DIGESTIVE DISEASEST32DK007198 · NIDDK · MAYO CLINIC ROCHESTER · PI Harmeet Malhi · 1986 to 2026
$8.9M
Pathophysiology of Biliary DiseaseR01DK057993 · NIDDK · MAYO CLINIC ROCHESTER · PI LARUSSO, NICHOLAS F., O'HARA, STEVEN P · 2001 to 2025
$7.1M
Pathophysiology of cholangiocyte responses to microbial pathogensR01AI089713 · NIAID · MAYO CLINIC ROCHESTER · PI O'HARA, STEVEN P · 2011 to 2015
$1.8M
NIAID NIH HHS AI089713NIAID NIH HHS R01 AI089713NIDDK NIH HHS DK007198NIDDK NIH HHS DK57993NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK057993
6 · The paper itself

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, idiopathic cholangiopathy. The role of cholangiocytes (biliary epithelial cells) in PSC pathogenesis is unknown and remains an active area of research. Here, through cellular, molecular and next-generation sequencing (NGS) methods, we characterize and identify phenotypic and signaling features of isolated PSC patient-derived cholangiocytes. We isolated cholangiocytes from stage 4 PSC patient liver explants by dissection, differential filtration and immune-magnetic bead separation. We maintained cholangiocytes in culture and assessed for: (i) cholangiocyte, cell adhesion and inflammatory markers; (ii) proliferation rate; (iii) transepithelial electrical resistance (TEER); (iv) cellular senescence; and (v) transcriptomic profiles by NGS. We used two well-established normal human cholangiocyte cell lines (H69 and NHC) as controls. Isolated PSC cells expressed cholangiocyte (eg, cytokeratin 7 and 19) and epithelial cell adhesion markers (EPCAM, ICAM) and were negative for hepatocyte and myofibroblast markers (albumin, α-actin). Proliferation rate was lower for PSC compared with normal cholangiocytes (4 vs 2 days, respectively, P<0.01). Maximum TEER was also lower in PSC compared with normal cholangiocytes (100 vs 145 Ωcm(2), P<0.05). Interleukin-6 (IL-6) and IL-8 (protein and mRNA) were both increased compared with NHCs and H69s (all P<0.01). The proportion of cholangiocytes staining positive for senescence-associated β-galactosidase was higher in PSC cholangiocytes compared with NHCs (48% vs 5%, P<0.01). Finally, NGS confirmed cholangiocyte marker expression in isolated PSC cholangiocytes and extended our findings regarding pro-inflammatory and senescence-associated signaling. In conclusion, we have demonstrated that high-purity cholangiocytes can be isolated from human PSC liver and grown in primary culture. Isolated PSC cholangiocytes exhibit a phenotype that may reflect their in vivo contribution to disease and serve as a vital tool for in vitro investigation of biliary pathobiology and identification of new therapeutic targets in PSC.

Indexed as

BiomarkersCell Line, TumorCell SeparationCellular SenescenceCholangitis, SclerosingFemaleHumansIntercellular JunctionsLiverMaleMiddle AgedBiomarkers

Identifiers

PMID25046437
PMCPMC4184949
OpenAlexW2082172262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.